Xenotropic murine leukemia virus-related virus may not be associated with human prostate cancer

	Tweet

The xenotropic murine leukemia virus-related virus (XMRV) which has previously been linked to prostate cancer has been found to have a dramatically lower prevalence among German prostate cancer patients, if any. Contrary to some reports, which have found XMRV in 40% of cases in patients in the US with familial prostate cancer, research published today in BioMed Central’s open access journal, Retrovirology has found no link between the two conditions in a large study of German prostate cancer patients.

The experimental research was undertaken by a team from the Robert Koch Institute and the Charité in Berlin, Germany, led by Norbert Bannert and Reinhard Kurth. They used real-time PCR and nested PCR techniques to genotype the RNase L gene (an interferon regulated antiviral defence gene) and detect the presence of the XMRV virus in samples collected from 589 prostate cancer patients between the years 2000 and 2006. Some samples were also tested for the presence of Env antibodies directed against XMRV using an ELISA.

Knowledge relating to the genetic susceptibility and risk factors of prostate cancer increase the likelihood of early detection and successful treatment of the disease. Previously, the HPC1 locus (hereditary prostate cancer locus-1) has been identified as a hereditary factor associated with a predisposition to prostate cancer.

The gene RNaseL is found within this locus. The RNase L gene codes for an endoribonuclease that is involved in the interferon-regulated antiviral defence pathway. Certain polymophisms in this gene in which the enzyme product has reduced activity have been reported by others as being linked to increased risk of prostate cancer (presumptively due to XMRV-infection) in the US and Japan.

In the current study, from the 589 prostate tumor samples, 76 were found to be homozygous for the previously reported RNase L presumptively XMRV-susceptible Q (R462Q) genotype, however, neither DNA nor RNA fragments of XMRV were detected in samples collected from the prostate cancers. ELISA results show that none of the patients had antibodies directed against XMRV, suggesting that in German prostate cancer patients at least, there is no evidence for XMRV infection or XMRV-linked prostate cancer even in individuals with the RNase L XMRV-susceptible Q genotype. According to Bannert, “a possible geographical restriction of XMRV and its associations with cases of prostate cancer should be studied closely”, adding that “the oncogenic potential of the virus must be thoroughly investigated in order to establish whether or not it can trigger the development of prostate cancer.”

###

Notes to Editors

1. Article:

Lack of evidence for xenotropic murine leukemia virus-related virus (XMRV) in German prostate cancer patients
Oliver Hohn, Hans Krause, Pia Barbarotto, Lars Niederstadt, Nadine Beimforde, Joachim Denner, Kurt Miller, Reinhard Kurth and Norbert Bannert
Retrovirology (in press)

During the embargo, article available here: http://www.retrovirology.com/imedia/5628949702874654_article.pdf?random=660160

Please name the journal in any story you write. If you are writing for the web, please link to the article. All articles are available free of charge, according to BioMed Central’s open access policy.

2. Retrovirology is a stringently peer-reviewed journal edited by Kuan-Teh Jeang (USA), Monsef Benkirane (France), Ben Berkhout (the Netherlands), Masahiro Fujii (Japan), Michael Lairmore (USA), Andrew Lever (UK), and Mark Wainberg (Canada) with the assistance of an internationally renowned Editorial Board. Retrovirology has an Impact Factor of 4.04. Read all the latest news from Retrovirology, on the Retrovirology blog

3. BioMed Central is an STM (Science, Technology and Medicine) publisher which has pioneered the open access publishing model. All peer-reviewed research articles published by BioMed Central are made immediately and freely accessible online, and are licensed to allow redistribution and reuse. BioMed Central is part of Springer Science+Business Media, a leading global publisher in the STM sector.

Contact: Charlotte Webber

44-020-319-22129
BioMed Central

RELATED STORIES:
High-Grade Prostate Cancer Linked to Diabetes   Study looks at using the immune system to reduce prostate cancer risk   Not all cancer patients improve lifestyle   Tall men at risk of early prostate cancer   Counseling helps sex life after prostate cancer   Study shows further benefits of noscapine for prostate cancer   Smoking Associated with Worse Outcomes in Patients with Prostate Cancer Treated by Radical Radiother   Low-income men show more high-risk prostate tumors   Prostate cancer hormone therapy hard on the heart   Smaller prostate size, more aggressive cancer   September is National Prostate Cancer Awareness Month   MicroRNA suppresses prostate cancer stem cells and metastasis   USC Leads International Program Aimed At Identifying Prostate Cancer Risk   Dramatic Outcomes in Prostate Cancer Study   Scientists see progress in prostate cancer tests   Gene variants in Japanese prostate cancer patients   Selenium-Protein Deficiency Raises Prostate Cancer Risk   Soft drink consumption may increase risk of pancreatic cancer   Prostate cancer patients disease free after 5 years likely to be disease free after 10 years   A Better Blood Test for Prostate Cancer   Older men get less effective prostate cancer care   Selected Men with Low-Risk Prostate Cancer Have Good Clinical Outcomes without Immediate Treatment

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]